Literature DB >> 11683243

Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.

R Holm1, A Müllertz, G P Pedersen, H G Kristensen.   

Abstract

PURPOSE: To compare the influence of the degree of fatty acid unsaturation (oleic [C18:], linoleic [C18:2], or linolenic acid [C18:3]), with the intestinal lymphatic transport of halofantrine free base from disperse systems in anesthetized rats.
METHODS: The mesenteric lymph duct was cannulated in anesthetized rats. Lipid vehicle containing halofantrine was administered by intraduodenal infusion. The concentration of halofantrine in blood and lymph samples was analyzed.
RESULTS: The rank order of the lymphatic transport of halofantrine was C18:2 > C18:1 > C18:3. Comparison of the area under the curve (AUC) from the three fatty acids showed no statistically significant differences between the AUCs from the lymph cannulated rats. In terms of rank order effects, the plasma concentrations of halofantrine were highest for the rats dosed C18:2 followed by C18:3 and C18:1.
CONCLUSIONS: Using C18:2 as a vehicle increased the lymphatic transport of halofantrine 16.6-fold over that observed for the system containing C18:3. The extent of lymphatic transport for the C18:1 system did not differ from the other two formulations, but the combined lymph and plasma data indicated that the C18:2 was the most suitable lipid vehicle for the oral delivery of halofantrine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683243     DOI: 10.1023/a:1013037927882

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  The portal transport of absorbed fatty acids.

Authors:  J Y KIYASU; B BLOOM; I L CHAIKOFF
Journal:  J Biol Chem       Date:  1952-11       Impact factor: 5.157

2.  Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.

Authors:  C J Porter; S A Charman; A J Humberstone; W N Charman
Journal:  J Pharm Sci       Date:  1996-04       Impact factor: 3.534

3.  Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.

Authors:  C J Porter; S A Charman; W N Charman
Journal:  J Pharm Sci       Date:  1996-04       Impact factor: 3.534

4.  The effect of different oils on the absorption of probucol in the rat.

Authors:  K J Palin; C G Wilson
Journal:  J Pharm Pharmacol       Date:  1984-09       Impact factor: 3.765

5.  The lymphocytic absorption of p,p'-DDT and some structurally-related compounds in the rat.

Authors:  S M Sieber
Journal:  Pharmacology       Date:  1976       Impact factor: 2.547

6.  A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions.

Authors:  A J Humberstone; G J Currie; C J Porter; M J Scanlon; W N Charman
Journal:  J Pharm Biomed Anal       Date:  1995-03       Impact factor: 3.935

7.  Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats.

Authors:  T Ichihashi; H Kinoshita; Y Takagishi; H Yamada
Journal:  J Pharm Pharmacol       Date:  1992-07       Impact factor: 3.765

8.  Similar bioavailability and lymphatic transport of benzo(a)pyrene when administered to rats in different amounts of dietary fat.

Authors:  J M Laher; M W Rigler; R D Vetter; J A Barrowman; J S Patton
Journal:  J Lipid Res       Date:  1984-12-01       Impact factor: 5.922

9.  Intrinsic lymphatic partition rate of mepitiostane, epitiostanol, and oleic acid absorbed from rat intestine.

Authors:  T Ichihashi; H Kinoshita; Y Takagishi; H Yamada
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

10.  Lipid vehicles for intestinal lymphatic drug absorption.

Authors:  M Cheema; K J Palin; S S Davis
Journal:  J Pharm Pharmacol       Date:  1987-01       Impact factor: 3.765

View more
  7 in total

1.  Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Authors:  René Holm; Christopher J H Porter; Anette Müllertz; Henning G Kristensen; William N Charman
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats.

Authors:  Mette Grove; Jeanet L Nielsen; Gitte P Pedersen; Anette Müllertz
Journal:  Pharm Res       Date:  2006-10-18       Impact factor: 4.200

Review 3.  Phospholipids and lipid-based formulations in oral drug delivery.

Authors:  Gert Fricker; Torsten Kromp; Armin Wendel; Alfred Blume; Jürgen Zirkel; Herbert Rebmann; Constanze Setzer; Ralf-Olaf Quinkert; Frank Martin; Christel Müller-Goymann
Journal:  Pharm Res       Date:  2010-04-22       Impact factor: 4.200

4.  Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats.

Authors:  Ditte M Karpf; René Holm; Henning G Kristensen; Anette Müllertz
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 5.  Characterising lipid lipolysis and its implication in lipid-based formulation development.

Authors:  Nicky Thomas; René Holm; Thomas Rades; Anette Müllertz
Journal:  AAPS J       Date:  2012-09-07       Impact factor: 4.009

6.  Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption.

Authors:  Yong-yan Bei; Xiao-yan Chen; Yang Liu; Jing-yu Xu; Wen-juan Wang; Zong-lin Gu; Kong-lang Xing; Ai-jun Zhu; Wei-liang Chen; Lin-seng Shi; Qin Wang; Xue-nong Zhang; Qiang Zhang
Journal:  Int J Nanomedicine       Date:  2012-04-03

7.  Block copolymer micelles as nanocontainers for controlled release of proteins from biocompatible oil phases.

Authors:  Andrew C Miller; Anna Bershteyn; Wuisiew Tan; Paula T Hammond; Robert E Cohen; Darrell J Irvine
Journal:  Biomacromolecules       Date:  2009-04-13       Impact factor: 6.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.